Review weighs survodutide phase 2 data and open questions in obesity

The wire

1. 01A Contemporary Clinical Trials review notes that in phase 2, adults with BMI of at least 27 and no diabetes lost up to 18.7% of body weight at 46 weeks on survodutide 4.8 mg versus 2.3% on placebo.
2. 02Survodutide pairs GLP-1 receptor agonism with glucagon receptor effects on energy expenditure and hepatic metabolism, positioning it against existing single and dual agonists.
3. 03Nausea, vomiting and diarrhea were common and tied to dose escalation; comparative effectiveness, durability, long-term safety and post-discontinuation effects remain unestablished.

From the source

Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties

Contemporary clinical trials · 2026 Oct 1 · Sergi CM et al.